Last reviewed · How we verify

Geref — Competitive Intelligence Brief

Geref (sermorelin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sermorelin. Area: Hematology.

marketed sermorelin Growth hormone-releasing hormone receptor Hematology Live · refreshed every 30 min

Target snapshot

Geref (sermorelin).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Geref TARGET sermorelin marketed sermorelin Growth hormone-releasing hormone receptor 1990-01-01
Egrifta TESAMORELIN ACETATE Theratechnologies marketed Growth Hormone Releasing Factor Analog Growth hormone-releasing hormone receptor 2010-01-01
Taxotere Docetaxel Sanofi marketed Microtubule Inhibitor [EPC] Growth hormone-releasing hormone receptor 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (sermorelin class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Geref — Competitive Intelligence Brief. https://druglandscape.com/ci/sermorelin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: